Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19

7 Apr 2022

Abstract excerpt

The SARS-CoV-2 3CL protease is a critical drug target for small molecule COVID-19 therapy, given its likely druggability and essentiality in the viral maturation and replication cycle. Based on the conservation of 3CL protease substrate binding pockets across coronaviruses and using screening, we identified four structurally distinct lead compounds that inhibit SARS-CoV-2 3CL protease. After evaluation of their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35393402
DOI: 10.1038/s41467-022-29413-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19PMID 35393402Read ↗

Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screeningSemantic proximity Read ↗

Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19Semantic proximity Read ↗

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read ↗

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Bio-Logical and Pharmacological ProfilingSemantic proximity Read ↗

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19Semantic proximity Read ↗

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected miceSemantic proximity Read ↗

High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent InhibitorSemantic proximity Read ↗

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19Semantic proximity Read ↗

The Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19Semantic proximity Read ↗

In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease InhibitorsSemantic proximity Read ↗

COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main proteaseSemantic proximity Read ↗

Recent advances in small-molecular therapeutics for COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.